At the same time, some of these molecules represent established or promising druggable targets in therapy of MCL including the spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase (BTK), phosphoinositide-3 kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), nuclear factor kappa B (NFκB) transcription factors and their regulators, mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1), and others. This evidence concerns the gene AKT1 and mantle cell lymphoma.